1. United States of America Stocks

  2. •

    Industrials

  3. •

    Industrial - Pollution & Treatment Controls
UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

UVFT
UV Flu Technologies, Inc.US flagOther OTC
0.00
USD
+0.00
- -
40,249.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.01
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
-0.05
-0.06
-0.02
-0.02
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
-0.05
-0.02
-0.01
-0.01
-0.01
- -
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
-0.06
-0.1
-0.06
-0.06
-0.06
-0.06
-0.05
Tangible Book Value per Share
- -
- -
- -
-0.05
- -
- -
- -
-0.01
-0.01
-0.01
Basic Weighted Avg Shares
28
36
36
11
15
38
56
69
82
107
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-377.87
-115.83
-505.66
-346.19
-490.51
-426.37
-894.29
-529.85
-345.24
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-1
-1
-1
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-381.87
-115.71
-525.66
-545.15
-527.15
-442.78
-873.35
-539.37
-385.34
Working Capital
- -
- -
- -
-1
- -
- -
- -
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
- -
- -
- -
-1
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-1,539.53
-469.1
-2,286.56
-2,571.78
-2,423.48
-1,745.82
-1,466.26
-1,191.7
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'15
Dec'16
Mar'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
85
132
133
Market Capitalization
2
2
2

Working Capital

FRC

•

in mil. unless spec.
Sep'15
Dec'16
Mar'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
457.15%
-1.02%
Free Cash Flow
- -
0.97%
-11.27%
Net Income, GAAP
- -
12.44%
-4.7%
Sales/Revenue/Turnover
- -
17.87%
54.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.01
- -
- -
- -
-0.01
2015
- -
- -
- -
- -
-0.01
2016
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Michael S. Ross
Full Time Employees
1
Sector
Industrials
Industry
Industrial - Pollution & Treatment Controls
Address
250 Parkway Drive Lincolnshire IL United States of America 60069
IPO Date
Nov 24, 2009
CIK
0001385310
Website
uvflutech.com
Similar Companies
Eco Safe Systems USA, Inc. (ESFS)
Environmental Clean Technologies Limited (ECT.AX)
Arq, Inc. (ARQ)
Hebei Sailhero Environmental Protection High-tech Co.,Ltd (300137.SZ)
Aduro Clean Technologies Inc. (ACT.TO)
Regenera Insights Inc. (DCTIF)
Business
UV Flu Technologies, Inc. (UVFT) develops, manufactures, and sells air purification systems and biotechnology products for the indoor air quality sector; its core offerings include the flagship ViraTech UV-400 model, which employs filterless UV-C technology to eliminate over 99% of airborne bacteria, viruses, and pathogens on first pass, alongside RxAir branded units certified as FDA Class II medical devices that target flu viruses including H1N1, coronaviruses, MRSA, strep, TB, and odors via high-intensity germicidal UV lamps in a patented killing chamber. The company, founded in 2006 and headquartered at 250 Parkway Drive, Suite 150 in Lincolnshire, Illinois, primarily operates in the United States, serving healthcare facilities, hospitals, athletics sectors, residential consumers, and commercial spaces with products that also reduce volatile organic compounds. In recent developments, Vystar Corporation acquired substantially all of UV Flu Technologies' assets around 2018, integrating its ViraTech and RxAir technologies into broader operations while maintaining focus on air purification innovations; earlier strategic moves included a 2014 distribution agreement with UCES for global retail and wholesale sales of ViraTech and RxAir units, alongside a marketing partnership with myVBO, and sales to Puravair, Inc. for athletics applications.